Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Kevin Hudson, Urs J. Hancox, Cath Trigwell, Robert McEwen, Urszula M. Polanska, Myria Nikolaou, Pablo Morentin Gutierrez, Alvaro Avivar-Valderas, Oona Delpuech, Phillippa Dudley, Lyndsey Hanson, Rebecca Ellston, Alys Jones, Marie Cumberbatch, Sabina C. Cosulich, Lara Ward, Francisco Cruzalegui, Stephen Green

Mol Cancer Ther (2016) 15 (5): 877–889.

https://doi.org/10.1158/1535-7163.MCT-15-0687

Published: 05 May 2016

View articletitled, Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

Includes: Supplementary data

Journal Articles

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER⁺ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Sylvie M. Guichard, Jon Curwen, Teeru Bihani, Celina M. D'Cruz, James W.T. Yates, Michael Grondine, Zoe Howard, Barry R. Davies, Graham Bigley, Teresa Klinowska, Kurt G. Pike, Martin Pass, Christine M. Chresta, Urszula M. Polanska, Robert McEwen, Oona Delpuech, Stephen Green, Sabina C. Cosulich

Mol Cancer Ther (2015) 14 (11): 2508–2518.

https://doi.org/10.1158/1535-7163.MCT-15-0365

Published: 03 November 2015

View articletitled, AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Includes: Supplementary data

Journal Articles

Abstract A24: Comprehensive PI3K pathway inhibition through combination of the PI3Kβ/δ inhibitor AZD8186 and the mTORC1/2 inhibitor AZD2014 drives tumor regression in vivo

Urs Hancox, Urszula Polanska, Lyndsay Hanson, Rebecca Ellston, Julia Maynard, Manfred Kraus, jon Curwen, Teresa Klinowska, Lara Ward, Francisco Cruzalegui, Stephen Green, Stefan Symeonides, Kathryn Cronin, Simon Barry

Mol Cancer Ther (2015) 14 (7_Supplement): A24.

https://doi.org/10.1158/1538-8514.PI3K14-A24

Published: 06 July 2015

View articletitled, Abstract A24: Comprehensive PI3K pathway inhibition through combination of the PI3Kβ/δ inhibitor AZD8186 and the mTORC1/2 inhibitor AZD2014 drives tumor regression in vivo

Journal Articles

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Mol Cancer Ther (2015) 14 (1): 48–58.

https://doi.org/10.1158/1535-7163.MCT-14-0406

Published: 13 January 2015

View articletitled, Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

Includes: Supplementary data

Journal Articles

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Kate F. Byth, Andrew Thomas, Gareth Hughes, Cheryl Forder, Alexandra McGregor, Catherine Geh, Sandra Oakes, Clive Green, Mike Walker, Nicholas Newcombe, Stephen Green, Jim Growcott, Andy Barker, Robert W. Wilkinson

Mol Cancer Ther (2009) 8 (7): 1856–1866.

https://doi.org/10.1158/1535-7163.MCT-08-0836

Published: 14 July 2009

View articletitled, AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

Includes: Supplementary data

Journal Articles

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Mol Cancer Ther (2008) 7 (9): 2955–2966.

https://doi.org/10.1158/1535-7163.MCT-08-0492

Published: 11 September 2008

View articletitled, AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Includes: Supplementary data

Journal Articles

Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases

Susan Ashwell, Benjamin Caleb, Chun Deng, Stephen Green, Michael Grondine, Heather Haye, Candice Horn, James Janetka, Dongfang Liu, Elizabeth Mouchet, Shannon Ready, Judith Rosenthal, Christophe Queva, Karen Taylor, Adam Sheehy, Graeme Walker, Anne White, Sonya Zabludoff

Mol Cancer Ther (2007) 6 (11_Supplement): A232.

Published: 01 November 2007

View articletitled, Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER⁺ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Abstract A24: Comprehensive PI3K pathway inhibition through combination of the PI3Kβ/δ inhibitor AZD8186 and the mTORC1/2 inhibitor AZD2014 drives tumor regression in vivo

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases

Email alerts

AACR Journals

Update search

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules

Abstract A24: Comprehensive PI3K pathway inhibition through combination of the PI3Kβ/δ inhibitor AZD8186 and the mTORC1/2 inhibitor AZD2014 drives tumor regression in vivo

Inhibition of PI3Kβ Signaling with AZD8186 Inhibits Growth of PTEN-Deficient Breast and Prostate Tumors Alone and in Combination with Docetaxel

AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

Preclinical identification of AZD7762, a novel, potent and selective inhibitor of Checkpoint kinases

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER⁺ Breast Cancer When Administered Using Intermittent or Continuous Schedules